Anavex Life Sciences Corp (AVXL)

[Investor2014]

No it doesn't.

Anavex 3-71. Simply, it has an even greater therapeutic potential than blarcamesine. It works therapeutically in doses fractional to those of blarcamesine

Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71

ANAVEX®3-71 was well tolerated in all cohorts receiving ANAVEX®3-71 in single doses ranging from 5 mg to 200 mg daily with no serious adverse events (SAEs) and no significant lab abnormalities in any subject. In the study,

ANAVEX®3-71 Phase 1 Top Line Data Conference Call

Confirmed also in Q&A session from 6:50. 5 - 50mg and 50 - 200mg. From 10:00 Missling knows very little about A3-71 compared to A2-73. The dose range is much broader with A3-71 up to 200mg vs. 60mg with A2-73

Not even 1 magnitude more than A2-73, if anyone knows what that means.